Throne Biotechnologies
OperatingThrone Biotechnologies Inc.
Biotech · Biotech · Paramus, NJ · Founded 2011
Find a cure type 1 diabetes, alopecia areata, and other autoimmune disease
Financials
FY2019–FY2020 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Fundraising history
Team
12 people
Dr. Zhao is an internationally-acclaimed scientist and doctor who specializes in immunology and stem cell biology. He is the first scientist to discover the CB-SC stem cells and is the inventor of Stem Cell Educator therapy to treat type 1 diabetes and other autoimmune diseases. He has held scientist and professorship positions at Hackensack Meridian Health and the University of Illinois at Chicago. He holds 9 patents and 60 publications and received his post-doctoral training from the University of Chicago.
Dr. Mazzone is a renowned endocrinologist and diabetologist with 40 years of experience as a clinical physician, professor, and scientist with over 135 publications; He was the Chairman of the Department of Medicine at the Northshore University Health of the University of Chicago, a tenured Professor of Medicine at Rush University Medical Center, and is the Founder and Director of University of Illinois at Chicago’s Center for Clinical and Translational Science. He was named “Castle Connolly’s America’s Top Doctors” and received his MD from the Northwestern University Medical School.
Mr. Lozano is a business executive with diplomatic correspondence to national and international heads of state for the top-down adoption of health and social services. His years of public service culminated in his post at the White House as Deputy Assistant to the President and Director of USA Freedom Corps. He was the Deputy Assistant to the President of the United States and a bi-partisan senior member of the White House under 5 presidents including George H. W. Bush and Barack Obama; He was appointed Director of USA Freedom Corps and received the Presidential Call to Service Award.
Mr. Zhao is an experienced entrepreneur with track-record of global successes in innovation development. He has a special focus on pediatric-centered healthcare; He is the founder of Skipper Yacht-share and was an innovation & marketing consultant on projects with Fortune 100 clients including McDonald’s, Disney, and Google. His MBA is from the University of Illinois Urbana-Champaign (UIUC).
Dr. King is an Associate Professor of Dermatology at Yale University School of Medicine, specializing in skin inflammatory and autoimmune skin diseases recalcitrant to first-line therapies. He has pioneered the use of Janus kinase (JAK) inhibitors in cutaneous diseases, in particular for alopecia areata and other cutaneous diseases. Dr. King received his B.A. at the University of California, his Ph.D. from Stanford University and his M.D. from Yale University School of Medicine. He completed medical internship at Massachusetts General Hospital and dermatology residency at Yale University School of Medicine.
Dr. Knight is specialized expert in field of diabetes, endocrinology, and metabolism; SHe is the Chair of Hackensack University’s Medical Center’s Diabetes Institute and Division Director of Endocrinology and Metabolism in the Department of Internal Medicine; She received her Fellowship in endocrinology at Albert Einstein College of Medicine & Montefiore Medical Center, and his MD from Harvard Medical School
Mr. Ludwig accomplished healthcare veteran with special personal interests in a diabetes cure; He is the former chairman of the board of Becton, Dickinson and Company (also known as BD), a global medical technology company, having served in that position from 2002 through 2012. He also served as BD’s chief executive officer (CEO) from January 2000 to September 2011 and as its president from May 1999 to December 2008. He is a Senior auditor at PWC; Board Director of CVS Health; Board of trustees at Hackensack University Medical Center; He received his MBA from Columbia University.
Mr. Ostrov had first-hand experience of the efficacy of Throne’s technology through the treatment of his 13 year old grandson for type 1 diabetes. He was the former Company Group Chairman of Johnson & Johnson’s North America Consumer and Personal Care businesses. He was also the President of CIBA Consumer Pharmaceutical (now Novartis), Company Group Chairman for Johnson & Johnson’s Worldwide Vision Care businesses, and Chairman and CEO of Bausch and Lomb. He received his MBA from Harvard University.
Show 3 more peopleShow fewer
Dr. Dudka has been a lifelong healthcare industry veteran including roles as an executive strategy consultant for Bristol Myers Squibb, Johnson & Johnson, & Pfizer. He was a fellow at the National Institute of Health and was the President of American College of Neuropsychopharmacology. He was a Professor at Princeton, Rutgers, and State University of New York. His expertise is in full operations-to-market drug launches, HIT and healthcare reengineering. He helps C-level executives and teams create strategic impact while tackling operations/market hurdles. He holds a PhD from Princeton University.
Rona has 20+ year Director of the Cellular Therapy Laboratory at New York Blood Center with specializations in developing stem cell, gene therapy, and immunotherapy products; She is an Associate Member of the Lindsley F. Kimball Research Institute, and the Head of Myeloproliferative Disorders (MPD) Research Laboratory; She received her PhD and Post-doctoral training from Mount Sinai School of Medicine in New York.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 0 of 5 annual reports (FY2021–FY2025)
Missing: 2021, 2022, 2023, 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form CFeb 25, 20220001665160-22-000346EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.